A Phase II Study of Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Latest Information Update: 04 Nov 2021
At a glance
- Drugs KITE 439 (Primary)
- Indications Squamous cell cancer; Vulvar intraepithelial neoplasia
- Focus Therapeutic Use
Most Recent Events
- 27 Oct 2020 Status changed from completed to discontinued.
- 23 Jun 2020 Status changed from recruiting to completed.
- 25 Mar 2020 Planned End Date changed from 30 Jul 2021 to 30 Jul 2024.